

GLRX5 Antibody (C-term) Blocking Peptide
Synthetic peptide
Catalog # BP5035b**Specification**

GLRX5 Antibody (C-term) Blocking Peptide - Product InformationPrimary Accession [Q86SX6](#)**GLRX5 Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 51218**Other Names**

Glutaredoxin-related protein 5, mitochondrial, Monothiol glutaredoxin-5, GLRX5, C14orf87

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

GLRX5 Antibody (C-term) Blocking Peptide - Protein Information**Name** GLRX5**Synonyms** C14orf87**Function**

Monothiol glutaredoxin involved in mitochondrial iron-sulfur (Fe/S) cluster transfer (PubMed:20364084, PubMed:23615440). Receives 2Fe/2S clusters from scaffold protein ISCU and mediates their transfer to apoproteins, to the 4Fe/FS cluster biosynthesis machinery, or export from mitochondrion (PubMed:20364084, PubMed:23615440, PubMed:24334290). Required for normal regulation of hemoglobin synthesis by the iron- sulfur protein ACO1 (PubMed:20364084).

Cellular Location

Mitochondrion matrix

GLRX5 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

GLRX5 Antibody (C-term) Blocking Peptide - Images

GLRX5 Antibody (C-term) Blocking Peptide - Background

GLRX5 is monothiol glutaredoxin involved in the biogenesis of iron-sulfur clusters. GLRX5 required for normal iron homeostasis. GLRX5 is required for normal regulation of hemoglobin synthesis by the iron-sulfur protein ACO1.

GLRX5 Antibody (C-term) Blocking Peptide - References

Bergmann, A.K., et al. *Pediatr Blood Cancer* 54(2):273-278(2010) Camaschella, C., et al. *Blood* 110(4):1353-1358(2007) Wingert, R.A., et al. *Nature* 436(7053):1035-1039(2005)